Fertility & Parenting Paths¶
Feminizing HRT suppresses spermatogenesis on a timeline of months. Recovery after an HRT pause is variable — some patients recover usable parameters in 3–6 months, some need 9–12+, some never recover and need surgical retrieval. Orchiectomy and vaginoplasty-with-orchiectomy permanently end gametogenesis from one's own tissue.
This page covers the practical decisions transfeminine adults face about biological reproduction and non-biological parenting before, during, and after transition. The focus is medical, logistical, and financial; the legal layer (parental rights, second-parent adoption, parentage acknowledgment) lives in Marriage & Family.
Pre-HRT banking is the only path with strong evidence
Sperm cryopreservation before initiating feminizing HRT works reliably for the large majority of transfeminine patients. Every other path — pausing HRT to recover spermatogenesis, TESE on suppressed testes, surgical retrieval at orchiectomy — is plausible but uncertain, with case-series outcomes ranging from full recovery to permanent azoospermia. Counsel in absolutes only where the data supports them.
The trans-specific evidence base is thin. The largest contemporary case series (Adeleye 2019, Cheng 2019, Barnard 2019) involve fewer than 100 patients each. WPATH SOC v8 Chapter 12 and ASRM both treat fertility counseling as a baseline standard of care while acknowledging the underlying evidence is limited.
Pre-HRT sperm cryopreservation¶
The cleanest, most evidence-supported path. WPATH SOC v8 and ASRM both recommend offering cryopreservation before initiating feminizing HRT in any patient who has not definitively foreclosed biological parenthood. Adeleye 2019 (UCSF cohort, n=78) found semen parameters in treatment-naive transfeminine patients were statistically lower than cisgender male reference populations at baseline — lower volume, concentration, and motility — but in the range that supports successful banking and later ART use in roughly 80% of patients.
Timing and yield¶
| Step | Typical protocol |
|---|---|
| Samples per collection | 2–3 samples spaced 48–72 hours apart |
| Abstinence per sample | 2–5 days |
| Vials per sample (target) | At least 3 |
| Pre-HRT yield (typical) | Enough for several IUI attempts or 1–2 IVF/ICSI cycles |
| Adequate-for-ART rate | ~80% of treatment-naive patients (Adeleye 2019) |
| Total time, counsel to HRT | 2–4 weeks |
Patients planning multiple children, sibling-genetic continuity, or sharing gametes with multiple partners should bank more aggressively. Patients with pre-existing varicocele, undescended-testis history, prior chemo/radiation, or Klinefelter mosaicism should expect lower baseline parameters and may need TESE regardless of HRT status.
Logistics¶
- Sperm banks (California Cryobank, Fairfax, NW Cryobank, ReproTech, regional academic banks) handle collection, analysis, freezing, and long-term storage. Most accept direct patient referral; some require an ART-clinic order.
- ART clinics integrate banking with later use. For patients planning reciprocal IVF with a partner or known gestational carrier, a single clinic can shorten the chain.
- Collection by masturbation in a clinic room is the default; home collection with rapid transport is acceptable at most banks within ~60 minutes. Electroejaculation under sedation is available for patients who cannot produce a sample by masturbation (dysphoria, anejaculation, religious or trauma-related barriers).
- Cryopreservation requires consent documentation specifying disposition on death, divorce, or loss of contact (use, donate, destroy). Revisit on every major life event — see Coming Out & Relationships for the relational sequencing.
Cost¶
| Item | Range | Notes |
|---|---|---|
| Initial collect/freeze | \(300–\)1,000 per sample | Multi-sample packages common |
| Annual storage | \(300–\)600/year | Multi-year prepay discounts (5/10-yr/lifetime) |
| Subsidies | Livestrong, AFP, Team Maggie's Dream | Need-based, application required |
State fertility-preservation mandates (NY, NJ, IL, CT, RI, NH) increasingly read gender-affirming HRT into the "iatrogenic infertility" framework where the state insurance commissioner has issued guidance. Self-funded ERISA plans are not bound by state mandates.
Sequencing relative to HRT¶
Most clinicians sequence: counseling → bank 2–3 samples over 1–2 weeks → confirm freeze viability on post-thaw analysis → begin HRT. Patients in acute dysphoric distress should be counseled that this 2–4 week delay is meaningful but bounded. Rushing HRT and foreclosing biological parenthood is a decision some patients regret.
Sperm cryopreservation after starting HRT¶
Feminizing HRT (estradiol ± antiandrogens, GnRH analogues) suppresses spermatogenesis. The degree and reversibility are variable and imperfectly predicted by any laboratory or clinical marker.
Recovery is plausible, not guaranteed
Older "stop HRT for 3–6 months and bank" guidance is not reliably effective. Adeleye 2019 and Barnard 2019 case series report some patients recover usable parameters in 3–6 months, some need 9–12+ months, and some never recover and require TESE. Histologic data from orchiectomy specimens (Schneider 2017; Matoso 2018) shows reduced spermatogenesis and Sertoli-cell-only patterns are common after even a few months of HRT — though pockets of preserved spermatogenesis often persist, supporting TESE as a backup.
Predictors of better recovery (suggestive, not validated): shorter HRT exposure, younger age at initiation, normal baseline parameters, no GnRH agonist exposure. Worse: long-duration HRT, GnRH agonists, older age. Prior orchiectomy or vaginoplasty-with-orchiectomy: no recovery possible.
Whether to pause HRT for retrieval¶
| Strategy | Pros | Cons |
|---|---|---|
| Pause HRT, attempt ejaculated banking | Most physiologic; lowest cost; no surgery | 3–6+ months off HRT; dysphoric re-masculinization; outcome uncertain |
| Continue HRT, proceed directly to TESE | No HRT pause; preserves continuity; avoids dysphoria | Surgical; higher cost; lower yield than treatment-naive ejaculate |
| Hybrid (pause, attempt, fall back to TESE) | Most flexible; salvages either outcome | Longest timeline; maximum cost exposure if both stages billed |
A patient considering pausing HRT should plan for a 6–12 month window of potential acute dysphoria — return of erections, libido shifts, possible re-masculinization of skin/hair/body composition — and have a mental-health plan in place. Some patients tolerate this well; some do not.
TESE (testicular sperm extraction)¶
Surgical sperm retrieval from the testis. Used when ejaculated-sample banking fails, is impossible, or is being deferred (e.g., concurrent with orchiectomy).
- Conventional TESE. Open biopsy of testicular tissue under local or general anesthesia. Multiple small wedge biopsies; tissue processed for sperm extraction in the embryology lab.
- Microdissection TESE (micro-TESE). Operating microscope used to identify dilated, opaque seminiferous tubules most likely to contain spermatogenesis. Higher yield in azoospermic and severely oligospermic patients; longer surgical time; requires a sub-specialty-trained urologist.
- Yield in transfeminine patients on HRT. Case series report sperm recovery in roughly 30–50% of patients undergoing TESE/micro-TESE after feminizing HRT, depending on HRT duration, age, and whether HRT was paused before retrieval. Outcomes data is limited and heterogeneous.
- Cost. \(5,000–\)15,000 for the surgical procedure plus anesthesia, plus embryology-lab processing and cryopreservation. Often not covered by insurance even where IVF is.
- Use pathway. TESE-retrieved sperm are typically usable only with ICSI (intracytoplasmic sperm injection), not IUI, because counts and motility are far below IUI thresholds. Plan ART pathway accordingly.
Surgical sperm retrieval at orchiectomy¶
Combining orchiectomy with sperm extraction is increasingly offered as a "last chance" for patients who did not bank pre-HRT and who are proceeding to orchiectomy. Mechanically straightforward — the testis is sent fresh to the embryology lab — but requires coordination between the surgical team, the embryology lab, and a fertility clinic in advance.
- Yield is similar to or somewhat lower than TESE in HRT-exposed patients.
- Incremental cost: \(3,000–\)8,000 for lab processing and freezing.
- Logistical pitfall: many surgical centers lack an in-house embryology lab, and tissue must be transported within a narrow window. Confirm chain of custody and lab capacity in writing before surgery.
- Consent must specifically authorize tissue harvest for cryopreservation, with disposition language matching standard sperm-bank consent.
Parenting paths compared¶
| Path | Uses own gametes? | Typical cost (US, all-in) | Timeline | Notes |
|---|---|---|---|---|
| Pre-HRT bank + reciprocal IVF | Yes | \(20,000–\)40,000 per cycle | Months once partnered | Gold-standard biological path with a partner who can carry |
| Pre-HRT bank + gestational carrier | Yes | \(100,000–\)200,000+ | 12–24 months | Highly state-variable; CA/CT/NV/NH/NJ/WA/DC most permissive |
| TESE / orchiectomy retrieval + IVF | Yes | \(25,000–\)55,000+ (retrieval + cycle) | 6–18 months | Lower yield; ICSI required; many insurance carve-outs |
| Donor sperm + partner gestation | No | \(500–\)1,500 per vial + ART | Months | Standard lesbian/SMBC framework; identity-release vs anonymous |
| Domestic foster-to-adopt | No | \(0–\)2,500 | 1–3 years | Affirming-state caseworker quality is load-bearing |
| International adoption | No | \(30,000–\)60,000 | 2–4 years | Most Hague countries de facto closed to trans applicants |
| Second-parent / confirmatory adoption | N/A | \(1,500–\)5,000 legal | 2–6 months | Locks in parental rights nationwide; do this regardless |
Donor sperm and gestational carriers¶
For patients who did not preserve sperm, whose preserved samples are not usable, or who do not want biological children from their own gametes. Identity-release ("open ID") vs. anonymous donor is the central choice; most banks now default to open-ID for new donors. Gestational-carrier jurisdictions are highly variable — see Marriage & Family for parentage architecture in restrictive states (LA, MI, NE).
Reciprocal IVF and partner gestation¶
The simplest biological-parenthood path for many trans women: bank pre-HRT, later use the banked sperm with a cis or transmasculine partner who can gestate. Reciprocal IVF and IUI both work. Bank early — even if no partner is in the picture at HRT initiation, a future partner who can carry is a common life trajectory.
Once a partner is involved, counsel both partners together. Donor backup, number of cycles, embryo disposition, and parental-rights paperwork are joint decisions. A Voluntary Acknowledgment of Parentage or court order of parentage at birth is the cleanest way to lock in the trans partner's parental status, even where the marital presumption applies.
Adoption¶
Domestic foster-to-adopt is state-administered with widely varying agency-level practice. In affirming states (CA, WA, OR, NY, MA, IL, MN, CO), trans applicants are generally accepted on the same terms as cis applicants. In hostile states, individual caseworker discretion and "religious exemption" laws (TN, MI, SC, VA, AL, OK) can produce de facto exclusion. Family Equality maintains a state-by-state agency directory. The home study is the load-bearing step; a trans-affirming social worker is worth seeking out.
International adoption outcomes for trans applicants are highly constrained. Most sending countries require married-couple or single-applicant status under their domestic law and may not recognize a US gender-marker change. Hague Convention countries (China, South Korea, Bulgaria, Colombia, Philippines, India, Haiti) each set their own eligibility; many have de facto closed to single, LGBTQ+, or trans applicants. An adoption agency with documented Hague-process and trans-client experience is essential.
Second-parent or confirmatory adoption for trans parents whose children were born to a partner via ART or prior relationship secures parental rights nationwide under full faith and credit. This is the gold standard regardless of the state's parentage presumption. See Marriage & Family.
Long-term fertility on stable HRT¶
For patients on long-term stable feminizing HRT who did not preserve sperm and are not pursuing fertility-preserving surgery:
HRT is not contraception
Spermatogenesis on stable HRT is presumed substantially suppressed but not necessarily zero. Pregnancy of a partner is documented in case reports of trans women on stable HRT, especially without antiandrogen co-suppression. Use barrier methods or other contraception if pregnancy avoidance matters.
After orchiectomy or vaginoplasty-with-orchiectomy, biological fertility from one's own gametes is permanently foreclosed unless sperm or testicular tissue was cryopreserved at or before the procedure. Periodic re-counseling about parenting plans is appropriate at major life transitions (new partner, marriage, surgical milestones) even years into HRT.
Sources¶
- Adeleye AJ, Reid G, Kao C-N, Mok-Lin E, Smith JF. Semen parameters among transgender women with a history of hormonal treatment. Urology. 2019; 124:136–141. UCSF cohort, n=78.
- Coleman E, et al. (2022). WPATH Standards of Care for the Health of Transgender and Gender Diverse People, Version 8, Chapter 12 (Reproductive Health and Fertility Preservation).
- ASRM Ethics Committee. Access to fertility services by transgender and nonbinary persons. Fertility and Sterility. 2021; 115(4):874–878.
- ASRM Practice Committee. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy. Fertility and Sterility. 2019; 112(6):1022–1033.
- Cheng PJ, Pastuszak AW, Myers JB, Goodwin IA, Hotaling JM. Fertility concerns of the transgender patient. Translational Andrology and Urology. 2019; 8(3):209–218.
- Barnard EP, Dhar CP, Rothenberg SS, et al. Fertility preservation outcomes in adolescent and young adult feminizing transgender patients. Pediatrics. 2019; 144(3):e20183943.
- Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology. 2017; 5(5):873–880.
- Matoso A, Khandakar B, Yuan S, et al. Spectrum of findings in orchiectomy specimens of persons undergoing gender confirmation surgery. Human Pathology. 2018; 76:91–99.
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017; 102(11):3869–3903.
- Family Equality. Family Building Guide and state-by-state agency directory; Alliance for Fertility Preservation; Livestrong Fertility; Team Maggie's Dream — subsidy and access programs.